Metopiron

Metyrapone, the active ingredient in Metopiron, is a 11β-hydroxylase inhibitor presented as an oral formulation for oral use. It is employed in diagnostic testing for Cushing's syndrome and may be used off‑label for treatment of the condition.

GNH USA supplies Metopiron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metyrapone acts on adrenal steroid synthesis, making it useful in disorders of cortisol excess.

- Diagnostic testing for Cushing's syndrome: helps assess endogenous cortisol production during suppression tests. - Treatment of Cushing's syndrome (off‑label): reduces cortisol synthesis when conventional therapy is unsuitable. - Evaluation of adrenal function in research settings: provides a pharmacologic tool to study 11β‑hydroxylase activity.

Metyrapone may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Nausea - Dizziness - Headache - Fatigue - Abdominal discomfort - Mild hypotension

Serious or Rare Side Effects: - Acute adrenal insufficiency - Severe hypotension or shock - Allergic reactions (rash, angioedema) - Hepatic dysfunction - Cardiac arrhythmias - Adrenal crisis in abrupt withdrawal

Use of Metyrapone requires careful clinical monitoring to avoid hormonal imbalance and related complications.

- Monitor cortisol levels: assess endocrine response before and during therapy. - Assess adrenal function: ensure baseline adrenal reserve is adequate. - Use with caution in hepatic impairment: adjust dose if liver function is compromised. - Avoid abrupt discontinuation: taper to prevent adrenal crisis. - Administer under specialist supervision: endocrinology input is recommended. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metyrapone can alter the activity of several drugs that share metabolic pathways or hormonal targets.

Major Interactions (Avoid): - Ketoconazole: strong CYP inhibition may increase Metyrapone plasma levels. - Rifampin: enzyme induction can markedly reduce Metyrapone effectiveness. - Phenytoin, carbamazepine: hepatic enzyme inducers that lower drug exposure. - High‑dose glucocorticoids: may counteract the intended cortisol‑lowering effect.

Moderate Interactions (Monitor Closely): - Oral contraceptives: hormonal changes may affect efficacy. - Antidepressants (e.g., SSRIs): potential additive effects on cortisol regulation. - NSAIDs: increased risk of gastrointestinal irritation when combined with Metyrapone.